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Background. Initiation of antiretroviral therapy (ART) in human immunodeficiency virus (HIV)-infected individuals with 
cryptococcal meningitis places them at risk for Cryptococcus-associated immune reconstitution inflammatory syndrome (C-IRIS). 
The relationship between antibody immunity and C-IRIS risk has not been investigated.
Methods. We compared plasma levels of immunoglobulins, C. neoformans glucuronoxylomannan (GXM) capsule-specific and 
laminarin (Lam)-binding IgM and IgG, and percentages of peripheral blood total and memory B cells between 27 HIV-infected 
patients with CM who developed C-IRIS and 63 who did not, and evaluated associations of these parameters with risk of C-IRIS.
Results. Prior to initiation of ART, plasma IgM, Lam-binding IgM (Lam-IgM), Lam-IgG, and GXM-IgM levels were significantly 
lower in patients who developed C-IRIS than those who did not. Multivariate analysis revealed significant inverse associations between 
C-IRIS and IgM (P = .0003), Lam-IgM (P = .0005), Lam-IgG (P = .002), and GXM-IgM (P = .002) independent of age, sex, HIV viral 
load, CD4+ T-cell count, and cerebrospinal fluid fungal burden. There were no associations between C-IRIS and total or memory B cells.
Discussion. Antibody profiles that include plasma IgM, Lam-IgM, Lam-IgG, and/or GXM-IgM may have value in furthering 
our understanding of C-IRIS pathogenesis and hold promise as candidate biomarkers of C-IRIS risk.
Keywords. HIV; cryptococcal meningitis; Cryptococcus-associated immune reconstitution inflammatory syndrome; IgM; IgG; 
memory B cells; laminarin; GXM.
 
Cryptococcal meningitis (CM) is a leading cause of human 
immunodeficiency virus (HIV)-associated mortality globally 
with an estimated 223 100 cases annually and 181 100 deaths 
in 2014 [1]. Individuals with CM are at risk for paradoxical 
Cryptococcus-associated immune reconstitution inflammatory 
syndrome (C-IRIS), a clinical worsening or recurrence of signs 
and symptoms of neurological deterioration due to the host 
immune response during antifungal treatment of cryptococco-
sis [2, 3]. Risk factors for C-IRIS include persistent cryptococ-
cal burden in the cerebrospinal fluid (CSF), poor CD4+ T-cell 
count recovery after antiretroviral therapy (ART) initiation [3], 
elevated plasma interleukin-5 (IL-5) and IL-7 levels [4], and 
paucity of CSF inflammation prior to ART initiation [5]. At 
present, there are no validated predictive biomarkers for HIV-
associated C-IRIS.
There are no published associations between anti-
body immunity and C-IRIS; however, ample data link 
specific antibody to resistance to human cryptococcosis. 
Glucuronoxylomannan (GXM) is the main constituent of the 
polysaccharide capsule of Cryptococcus neoformans. Levels 
of GXM-binding IgM were lower among HIV-infected than 
HIV-uninfected individuals [6, 7], HIV-infected individuals 
who developed cryptococcosis compared to those who did 
not [7], and HIV-uninfected solid organ transplant recipients 
who developed cryptococcosis posttransplant than those who 
did not [8]. Notably, GXM-IgG directly associates with risk for 
CM, being higher in HIV-infected than HIV-uninfected, and 
HIV-infected and HIV-uninfected individuals with CM than 
controls without CM [6, 9–11].
Prior work also shows that HIV-infected as well as HIV-
uninfected individuals with a history of cryptococcosis had 
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lower percentages of peripheral blood B, memory B, and IgM 
memory B cells than HIV-infected and HIV-uninfected per-
sons who did not [7, 10]. IgM memory B cells are the main 
source of human serum IgM [12]. Antibodies produced by 
these cells, also called naturally occurring (natural) antibod-
ies, have the ability to bind conserved carbohydrate moieties, 
such as β-glucans, found on microbes, including C.  neofor-
mans [13–15]. Data from experimental cryptococcosis models 
support a role for natural antibody in resistance to C. neofor-
mans. Natural serum IgM and/or B-1 cells, mouse homologs 
of IgM memory B cells [12], reduced C. neoformans dissemina-
tion from lungs to brain in mice [7, 16, 17]. Natural IgM also 
enhanced alveolar macrophage phagocytosis of C. neoformans 
in IgM-deficient [7] and B and T-cell–deficient Rag1−/− mice 
[17], and naive B-1 cells enhanced lung antifungal immunity 
in B-1-cell–depleted wild-type mice and reduced C.  neofor-
mans dissemination to the brain [16]. Data showing a mouse 
β-(1,3)-glucan mAb reduced C.  neoformans growth in vitro 
and protected mice against lethal C. neoformans infection [18] 
provides further evidence that natural antibody may enhance 
resistance to C. neoformans as there are β-(1,3)-glucans on the 
C. neoformans cell wall [13, 18, 19].
To investigate relationships between C-IRIS and antibody 
immunity, we determined levels of plasma immunoglobulins, 
naturally occurring, IgM, laminarin (Lam)-IgM and Lam-IgG, 
GXM-IgM and GXM-IgG, pustulan-IgM and pustulan-IgG, 
along with peripheral blood B-cell subset phenotypes in a 
previously described cohort of patients with HIV-associated 




The cohort was previously described [3]. It included 90 ART-
naive, HIV-infected patients with a first episode of CM, of 
whom 27 developed possible or probable C-IRIS after ART 
initiation (C-IRIS group) and 63 who did not (no–C-IRIS 
group). Patient recruitment, inclusion criteria, the study pro-
tocol, and clinical outcomes were reported previously [3]. In 
brief, all patients received induction therapy with amphotericin 
B 1 mg/kg for 14 days followed by consolidation therapy with 
fluconazole 400 mg for 8–12 weeks, and ART was initiated on 
or about day 18 of antifungal therapy. The data reported herein 
were obtained with plasma and peripheral blood mononuclear 
cells (PBMCs) collected at ART initiation (W0), and 4 (W4) and 
12 (W12) weeks after ART initiation. Written informed consent 
was given by the patients or their families and ethics approval to 
the parent study was granted by the Biomedical Research Ethics 
Committee of the University of KwaZulu-Natal (BF053/09), 
Monash University (20161197839), and University of Western 
Australia (RA/4/1/2541) [3].
Measurement of Plasma Immunoglobulin Concentrations
Plasma IgM, IgG1, and IgG2 concentrations were determined 
on samples obtained at W0, W4, and W12 by Luminex accord-
ing to the manufacturer’s instructions. In brief, a prediluted 
standard, assay buffer, and patient samples were added to the 
wells of a 96-well plate in duplicate. Then the plate was incu-
bated with mixed beads at room temperature for 1 hour, the 
plate was washed and incubated with anti-human κ and λ light 
chain detection antibodies, incubated for 30 minutes at room 
temperature in the dark, and then with streptavidin-phyco-
erythrin. The content of the wells were read using Luminex 200 
(EMD Millipore, Billerica, MA) with xPONENT software.
Measurement of Antibodies to GXM, Lam, and Pustulan
Titers of GXM-binding IgM and IgG, Lam-binding IgM and 
IgG, and pustulan (a β-(1,6)-linked linear glucan [20])-binding 
IgM and IgG, were determined using plasma obtained at W0, 
W4, and W12. GXM enzyme-linked immunosorbent assays 
(ELISAs) were performed as described [10, 21] using GXM 
from C. neoformans 24067 (serotype D) prepared as described 
[22]. This GXM exhibits cross reactivity with serotype A GXM 
[23] and is used extensively for serological analyses in mice and 
humans [6, 10, 17].
As Lam is an algal polysaccharide consisting mainly of β-(1–
3)-glucan with rare β-(1–6)-glucan linkages [24], Lam antibod-
ies were measured as a surrogate for β-(1–3)-glucan antibodies 
as described [14]. Lam (Sigma Chem, St. Louis, MO) and pus-
tulan (InvivoGen, San Diego, CA) ELISAs were performed as 
described [14] with modification of the amount of coating anti-
gen. First, we used 10 µg/mL rather than 50 µg/mL [14] of each 
glucan as the coating antigen. Then, to confirm Lam specificity 
and extend results to another β-glucan, pustulan, we repeated 
the assays with 5  µg/mL of coating antigen. Briefly, 96-well 
polystyrene plates (Costar; Corning, Kennebunk, ME) coated 
with 10  μg/mL (or 5  μg/mL) of Lam or pustulan were incu-
bated with serially diluted plasma, washed, incubated with goat 
anti-human alkaline phosphatase-labeled IgM or IgG (Southern 
Biotech, Birmingham, AL), and then with p-nitrophenyl phos-
phatase (Sigma-Aldrich, St. Louis, MO). Absorbance was 
measured at 405  nm with a VERSAmax ELISA plate reader 
(Molecular Devices, Sunnyvale, CA). The highest dilution to 
give a signal at 2 times the optical density background (wells 
with no sera) was defined as the antibody titer.
Peripheral B-Cell Immunophenotyping
The phenotypes of peripheral blood B cells were determined 
by flow cytometry as previously described [7, 10]. Briefly, 
PBMCs obtained at W0, W4, and W12 stained with LIVE/
DEAD Cell Stain (Invitrogen, Eugene, OR) were incubated 
with the following phenotyping reagents (BD Biosciences): 
mouse anti-human PerCP-Cy5.5-conjugated CD27, Alexa 
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and allophycocyanin-conjugated IgM, after which cells were 
washed and fixed with 2% paraformaldehyde. Single-color 
controls and fluorescence-minus-one controls were included 
to ensure proper compensation and gating. Counting Beads 
(Invitrogen, Eugene, OR) were included in all samples. Data 
were collected on a LSR-II (Becton Dickinson) interfaced 
to a Windows FACSDiva software. Among living cells, per-
centages of the following cell types were identified with 
FlowJo version 10 software (Tree Star): total B cells (CD19+), 
total memory B cells (CD19+CD27+), IgM+-only memory B 
cells (CD19+CD27+IgM+IgD−), IgM+IgD+ memory B cells 
(CD19+CD27+IgM+IgD+), and class-switched memory cells 
(CD19+CD27+IgM−IgD−) (Supplementary Figure 1).
Statistical Analysis
We compared serological and B-cell measurements at W0, W4, 
and W12 by non-parametric Mann-Whitney U test without and 
with adjustment for previously reported age, sex, CD4+ T-cell 
counts, HIV viral load (VL), and CSF fungal burden [3]. Then, 
we estimated associations between ART initiation values and 
risk of C-IRIS using multivariable logistic regression. Included 
in the parametric model was previously reported age, sex, CD4+ 
T-cell counts, HIV VL, and CSF fungal burden [3]. We also 
looked at the correlation between baseline serological markers 
(Supplementary Table 1). A P value of <.05 was considered sta-
tistically significant.
RESULTS
IgM, Lam-IgM/IgG, GXM-IgM, and Pustulan-IgM/IgG Were Lower in the 
C-IRIS Group
At ART initiation (W0), plasma IgM (P  <  .0001; Figure  1), 
Lam-IgM (P  =  .0001; Figure  2A), Lam-IgG (P  =  .004; 
Figure 2B), and GXM-IgM (P = .0003; Figure 2C) were each 
significantly lower in patients who developed C-IRIS than 
those who did not. Levels of Lam-IgM, but not Lam-IgG, were 
also significantly lower in the C-IRIS than no–C-IRIS group 
when 5  μg/mL was used as the coating antigen (P  =  .003; 
Supplementary Figure  2), as were titers of pustulan-IgM 
(P  <  .0001; Supplementary Figure  3A), and pustulan-IgG 
(P  <  .0001; Supplementary Figure  3B). There was no signif-
icant difference in titers when comparing Lam-IgM using 
5  μg/mL versus 10  μg/mL of Lam as the coating agent. We 
also analyzed post-ART samples to ascertain the effect of ART 
on antibody profiles. The C-IRIS group had significantly lower 
Lam-IgM at W4 (P = .007; Supplementary Table 2), Lam-IgG 
at W4 (P = .01; Supplementary Table 2) and W12 (P = .007; 
Supplementary Table  2), and plasma IgM at W4 (P  <  .0001; 
Figure 3A) and W12 (P =  .006; Figure 3B). Significant find-
ings held after adjustment for age, sex, HIV VL, CD4+ T-cell 
counts, and CSF fungal burden (Supplementary Table 2).
Higher IgM, Lam-IgM, GXM-IgM, and Pustulan-IgM/IgG Levels at 
Baseline Were Associated With Lower Risk of C-IRIS
At ART initiation, log2 IgM was inversely associated with 
C-IRIS independent of age, sex, CD4+ T-cell count, HIV VL, 
and CSF fungal burden (odds ratio [OR] 0.26; 95% confidence 
interval [CI], 0.12–0.54; P =  .0003). Inverse associations were 
also observed for Lam-IgM (OR 0.55; P  =  .0005), GXM-IgM 
(OR 0.62; P =  .002), pustulan-IgM (OR 0.25; P =  .0006), and 
pustulan-IgG (OR 0.44; P  =  .003) independent of adjustment 
factors (Figure  4). For Lam-IgG, an inverse association was 
found when 10  µg/mL (OR 0.44; P  =  .002), but not 5  µg/mL 
Lam was the ELISA coating agent. Total IgM levels at baseline 
were significantly correlated with GXM-IgM (r = 0.63; P < .05), 
GXM-IgG (r = 0.33; P < .05), and Lam-IgM (r = 0.45; P < .05) 
(Supplementary Table 1).
Total and Memory B-Cell Subset Did Not Differ Between the C-IRIS and 
No–C-IRIS Group
There were no significant differences in the number or per-
centage of B-cell subsets (total or total memory, IgM+IgD+, 
IgM+-only, or switched memory B cells) between the C-IRIS 
and no–C-IRIS groups (Supplementary Figure 4). There were 
also no significant associations between any B-cell subset and 
C-IRIS or plasma IgM, IgG1, or IgG2, or GXM- or Lam-IgM or 
IgG at baseline (data not shown).
Baseline CD4+ T-Cell Counts Were Directly Correlated With Plasma IgM Level
There was a direct correlation between CD4+ T-cell counts and 
plasma IgM levels at ART initiation in an unadjusted analysis of 
the entire cohort (r = 0.39; P = .02). A previous report showed 
the C-IRIS group had lower CD4+ T-cell counts at baseline in 
an unadjusted analysis (median 16 vs 36 cells/μL; P = .015) [3]. 
No significant associations were identified between CSF fun-
gal burden or HIV VL [3] at ART initiation with Ig levels or 












Figure 1. Plasma IgM concentration in Cryptococcus-associated immune recon-
stitution inflammatory syndrome (C-IRIS) and no–C-IRIS groups at week 0.  Data 
were obtained by Luminex. Median values (horizontal lines in the center), and inter-
quartile ranges (upper and lower horizontal lines) are shown. Asterisks indicate 
significant comparison between groups: ****P  <  .0001 by the Mann-Whitney U 
test. Significant findings remained after adjustment for age, sex, HIV viral load, 
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no correlations between changes in CD4+ T-cell counts and 
changes in serology or B-cell levels over time (data not shown).
DISCUSSION
The major finding of this study is that, at ART initiation, lev-
els of plasma IgM, GXM-IgM, and β-glucan-binding (Lam and 
pustulan)-IgM were lower in the C-IRIS than no–C-IRIS group 
and inversely associated with development of C-IRIS after 
adjustment for age, sex, CD4+ T-cell count, HIV VL, and CSF 
fungal burden. Lam-IgG was significantly lower in the C-IRIS 
than no–C-IRIS group when 10 µg/mL, but not 5 µg/mL, Lam 
was the ELISA coating antigen. While association does not 
establish causation, these findings support the idea that GXM-
IgM and naturally occurring β-glucan-reactive antibodies may 
play a role in preventing CM and/or C-IRIS. Though more work 
is needed to confirm this hypothesis, it is consistent with pre-
clinical data in mice. Mouse and human monoclonal (mAb) 

























Figure 3. Plasma IgM concentration in Cryptococcus-associated immune reconstitution inflammatory syndrome (C-IRIS) and no–C-IRIS groups at (A) week 4, and (B) week 
12. Data were obtained by Luminex. Median values (horizontal lines in the center), and interquartile ranges (upper and lower horizontal lines) are shown. Asterisks indicate 
significant comparisons between groups: **P < .01, ****P < .0001 by the Mann-Whitney U test. Significant findings remained after adjustment for age, sex, HIV viral load, 










































































Figure 2. Titers of (A) laminarin (Lam)-IgM, (B) Lam-IgG, (C) glucuronoxylomannan (GXM)-IgM, and (D) GXM-IgG in Cryptococcus-associated immune reconstitution inflam-
matory syndrome (C-IRIS) and no–C-IRIS groups at week 0. Data were obtained by enzyme-linked immunosorbent assays (ELISA) using 10 µg/mL Lam or GXM as the coating 
antigen. Data are median values (horizontal lines in the center), and interquartile ranges (upper and lower horizontal lines). Asterisks indicate significant comparisons 
between groups: **P < .01, ***P < .001, ****P < .0001 by the Mann-Whitney U test. Significant findings remained after adjustment for age, sex, HIV viral load, CD4+ T-cell 
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C.  neoformans, enhance antifungal immunity, and promote 
clearance of GXM, an immunosuppressant, in mice [25]. 
C. neoformans-selected mouse B-1 cells, which are IgM+ mem-
ory B-cell homologs, produced IgM that reacted with Lam and 
GXM [16]. In addition, naturally occurring serum IgM and/or 
B-1 cells enhanced antifungal immunity in the lungs, reduced 
C.  neoformans dissemination to the brain [17, 21], and pro-
moted a “wild type” inflammatory pulmonary response [17] in 
mice. The foregoing data, along with a study showing a mouse 
β-(1–3)-glucan mAb (2G8) inhibited C.  neoformans budding 
and growth in vitro and protected mice against lethal C. neofor-
mans [18], support the idea that natural antibody mediates host 
benefit against C. neoformans. The correlation between plasma 
IgM and Lam- and GXM-IgM suggests that these antibodies 
may be part of the same natural antibody repertoire, though 
separate studies are needed to determine the B-cell subset/s that 
produce these antibodies.
Human studies also support the idea Lam antibodies may 
contribute to antifungal immunity to C.  neoformans. Human 
serum antibodies bind Lam and other β-glucans on the 
C.  neoformans cell wall [13, 14, 16, 26]. Lam antibodies were 
associated with a better prognosis in patients with candidiasis 
[27], and C. neoformans β-glucosylceramide-binding antibod-
ies from patients with cryptococcosis inhibited C. neoformans 
binding in vitro [26]. The ability of β-glucan antibodies to bind 
fungal elements was part of the rationale for an experimen-
tal Lam-based conjugate vaccine for fungi [28] that protected 
mice against Candida and Aspergillus [28, 29]. The aforemen-
tioned β-(1–3)-glucan mAb 2G8, which protected mice against 
C. neoformans [18] and Candida [28], was produced from mice 
immunized with this vaccine [28].
At present, we do not know how GXM-IgM or Lam-IgM 
may mediate a beneficial effect in patients being treated for 
CM. Mouse and human GXM-IgM mAbs promote effector cell 
phagocytosis of C. neoformans in mice [30, 31]. Mouse GXM 
mAbs also reduce C. neoformans budding in vitro and enhance 
clearance of GXM [32]; this effect was also observed in a clinical 
trial of a GXM mAb in patients with CM [33]. Thus, it is reason-
able to posit that higher levels of GXM-IgM in the no–C-IRIS 
cohort may have contributed to their lower fungal burdens, 
while lower levels may contribute to C. neoformans persistence 
in the CNS, as reported for patients with C-IRIS [3, 5, 34]. 
Our data do not suggest a role for GXM-IgG in resistance to 
C-IRIS. In fact, higher levels of GXM-IgG were associated with 
risk for and/or active cryptococcosis in HIV-infected and HIV-
uninfected patients [6, 10, 11]. Thus, our finding that GXM-IgG 
levels were not different between the cohorts may be a reflection 
of the similar fungal burdens of these groups at the time of ART 
initiation.
Available data suggest β-glucan antibodies may exert a direct 
antifungal effect. The aforementioned β-(1–3)-glucan mAb 
that protected mice against C. neoformans in vivo did not pro-
mote phagocytosis of C. neoformans [18]. Instead, it inhibited 
C. neoformans budding and growth, as did human antibodies to 
a β-glucan-linked C. neoformans cell wall moiety [18, 26]. We 
did not perform growth inhibition studies with samples from 
the cohort in this study because the patients were on antifungal 
therapy. However, fungal killing may not directly associate with 
protection; neither natural serum IgM nor B-1 B cells apprecia-
bly reduce C. neoformans lung fungal burdens in experimental 
cryptococcosis, even though they mediate protection against 
dissemination [7, 16, 17]. The inverse associations of total IgM, 
GXM-IgM, and Lam-IgM with C-IRIS in this study support the 
idea that some of these antibodies may reduce the inflammatory 
response to C. neoformans that can occur with ART initiation. 
Data from a B-cell–deficient mouse model show that absence 
of B cells and natural antibody led to a disorganized pulmo-
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Figure 4. Associations between log2 transformed plasma antibody titers and Cryptococcus-associated immune reconstitution inflammatory syndrome (C-IRIS) at week 0 
(n = 90, 27 C-IRIS events). Associations of each serological marker with C-IRIS status were adjusted for age, sex, contemporaneous CD4+ T-cell count, log10 HIV viral load, 
and log10 cerebrospinal fluid fungal burden using logistic regression model. Laminarin (Lam)- and glucuronoxylomannan (GXM)-Ig data were obtained using 10 µg/mL of the 
coating agent and pustulan-Ig using 5 µg/mL of the coating agent. Significant association with Lam-IgG was lost when 5 µg/mL of the coating agent was used. Abbreviations: 
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same lines, natural serum IgM enhanced phagocytosis and 
restored wild-type lung histology in IgM and B and T-cell 
(Rag1−/−) deficient mice [17, 21]. Thus, natural antibodies may 
have dual activities, enhancing phagocytosis and dampening of 
inflammation. Regarding the latter, natural antibody can inhibit 
inflammation in mice [35] and has been proposed as adjuvant 
immunotherapy for inflammatory conditions [35]. Therefore, 
it is reasonable to posit that β-glucan IgM may contribute to 
beneficial immunomodulation in patients with cryptococcosis, 
resulting in reduced inflammation.
Plasma from patients in our study bound β-(1–3)-glucan in 
ELISAs using 10 and 5 µg/mL Lam as the capture antigen. These 
amounts of Lam are 5 and 10 times less than the amount used by 
others to establish β-glucan binding in normal human sera [14, 
27]. The no–C-IRIS group had higher levels of Lam-IgM irre-
spective of the amount of coating antigen. On the other hand, 
there was no difference in Lam-IgG levels between the groups 
when 5 µg/mL Lam was used as the coating antigen. This may 
reflect the fact that IgM has greater avidity leading to continued 
reactivity at a similar titer. It may also reflect that Lam-IgM and 
Lam-IgG have different β-glucan specificities. Although studies 
to address this question were beyond the scope of this study, we 
note β-(1–3)- and β-(1–6)-glucan mouse mAbs differed by iso-
type and exhibited different biological activity against Candida 
[36]. Plasma from both cohorts also reacted with pustulan, a 
linear β-(1-6)-glucan. Pustulan-IgM and IgG were each signifi-
cantly higher in the no–C-IRIS group, as reported for normal 
sera [14]. Although antibodies may also bind Lam via branched 
interchain hydrogen bonds [37], our data demonstrate repro-
ducible differences in Lam-IgM between the cohorts at a sub-
stantially lower concentration than used in other studies [14]. 
In addition, a sample from 1 C-IRIS and 1 no–C-IRIS patient 
was inhibited by the aforementioned β-(1–3)-glucan mAb (data 
not shown). Unfortunately, we did not have enough of this mAb 
to test more sera.
HIV infection results in a deficiency of IgM+ memory B cells 
[38] and a myriad of B-cell defects, including apoptosis [39], 
reduced antibody levels [40], and dysfunctional B-cell differ-
entiation [41]. Previous studies comparing HIV-infected and 
HIV-uninfected patients with cryptococcosis to normal (or 
HIV-infected) controls showed IgM+ memory B-cell levels were 
lower in patients with cryptococcosis. In our study, in which all 
patients had CM, B-cell levels did not differ between the C-IRIS 
and no–C-IRIS group. Notably, patients in both cohorts were 
acutely ill with extremely low CD4+ T-cell counts prior to ART 
initiation and had substantially lower IgM+ memory B-cell lev-
els than those reported for other HIV-infected patients [7, 41]. 
Given that HIV infection is associated with impaired B-cell acti-
vation and deranged production of chemokines and cytokines 
[34, 42], lower antibody levels in C-IRIS patients in this study 
may reflect B-cell dysfunction. Consistent with this idea, pre-
ART levels of plasma IL-5 and IL-7, each of which affect B-cell 
function [4], and CSF CCL2 and CCL3/CXCL10 ratios were 
higher in a subset of the C-IRIS cohort [43]. Human B cells also 
produce CXCL10 [44]. We did not seek associations between 
cytokine levels and our findings because ART-initiation cyto-
kine levels were not available for more than half of the C-IRIS 
cohort we studied. Without a control group of HIV-infected 
patients that did not have C. neoformans, we could not examine 
effects of C. neoformans, HIV, ART, or coinfection on memory 
B-cell subsets or function.
We recognize that our data are descriptive and our discus-
sion of how differences in natural antibodies between the 
C-IRIS and no–C-IRIS cohort may affect C-IRIS pathogenesis 
is speculative. Nonetheless, our findings are clear and suggest 
reduced levels of natural antibodies that react with β-glucans 
and/or GXM deserve further consideration as potential bio-
markers of risk for C-IRIS at ART initiation. Lam-IgM levels 
increased post-ART in both cohorts, but the significant differ-
ence between the C-IRIS and no–C-IRIS group was unchanged. 
This leads us to wonder if the differences we observed may have 
been present at the time of presentation with CM. We can only 
speculate about this possibility, as preantifungal therapy sam-
ples were not available. Nonetheless, the pathogenesis of C-IRIS 
includes other factors in addition to ART initiation [2], includ-
ing the inflammatory response to fungal antigens, which occurs 
in the setting of the proinflammatory effects of amphotericin 
[45]. As a shorter amphotericin induction period was nonin-
ferior to the standard 2-weeks regimen in resource-limited 
settings [46], it will be interesting to learn if this is also asso-
ciated with a lower risk for C-IRIS. Notably, paradoxical clin-
ical deterioration with antifungal therapy occurs in mice [47] 
and in HIV-uninfected patients [48, 49]. Therefore, control of 
the inflammatory response that may occur upon initiation of 
antifungal therapy may also be a critical determinant of clinical 
outcome in HIV-associated CM.
Our study has several limitations. As we did not have a con-
trol population with HIV infection alone, we cannot determine 
if HIV or C. neoformans infection or both affected antibody lev-
els, and, as we did not have samples from the time of clinical 
presentation with CM, we could not assess the effect of antifun-
gal therapy on risk for C-IRIS. Regarding our statistical anal-
ysis, we may have falsely claimed significance due to multiple 
comparisons done and the close correlation between some of 
the variables (Supplementary Table  1). However, associations 
between plasma IgM, Lam-IgM, and GXM-IgM further support 
the observed inverse association between natural antibodies 
and C-IRIS, as Lam and GXM antibodies may be produced by 
the same B-cell subsets [16]. Finally, given that C. neoformans 
sheds its capsule during infection, particularly in the presence 
of antifungals [50], shed GXM could form complexes and affect 
GXM antibody measurements. While this would underestimate 
antibody levels, acid dissociation of antibody complexes did not 
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In summary, our data revealed significant differences in 
plasma IgM, Lam-IgM, and GXM-IgM levels between patients 
who developed C-IRIS and those who did not before and after 
ART initiation. These findings are novel and important to the 
C. neoformans field as they contribute more data to support a 
role for antibody immunity in human cryptococcosis. We sub-
mit that one or a signature of these antibodies may predict risk 
for C-IRIS in patients on antifungal therapy. Given the dev-
astating prognosis that C-IRIS carries, the ability to identify 
patients who may develop C-IRIS would improve the care and 
management of patients with CM. While more work is needed 
to determine mechanisms by which the antibody populations 
affect the pathogenesis of C-IRIS, we believe the associations 
identified in this study deserve further clinical and basic science 
investigation.
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benefit the reader, the posted materials are not copyedited and 
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